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ABSTRACT 
The free fatty acid receptor 1 (FFA1/GPR40) is a potential target for treatment of type 2 
diabetes. Although several potent agonists have been described, there remains a strong need for 
suitable tracers to interrogate ligand binding to this receptor. We address this by exploring 
fluorophore-tethering to known potent FFA1 agonists. This led to the development of 4, a high 
affinity FFA1 tracer with favorable and polarity-dependent fluorescent properties. A close to 
ideal overlap between the emission spectrum of the NanoLuciferase receptor tag and the 
excitation spectrum of 4 enabled the establishment of a homogenous BRET-based binding assay 
suitable for both detailed kinetic studies and high throughput competition binding studies. Using 
4 as a tracer demonstrated that the compound acts fully competitively with selected synthetic 
agonists but not with lauric acid and allowed for the characterization of binding affinities of a 
diverse selection of known FFA1 agonists, indicating that 4 will be a valuable tool for future 
studies at FFA1. 
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INTRODUCTION 
Free fatty acid receptor 1 (FFA1, also known as GPR40) is a 7TM receptor activated by 
medium- and long-chain free fatty acids that in recent years has attracted much attention as a 
potential target for the treatment of type 2 diabetes. FFA1 is highly expressed in pancreatic ² -
cells where it enhances insulin secretion in a glucose concentration-dependent manner. It may 
therefore represent a target for safe new insulin secretagogues devoid of the risk of 
hypoglycemia associated with the currently used sulfonamides.1 FFA1 is also highly expressed 
in enteroendocrine cells and regulates incretin hormone secretion, driving further interest in this 
receptor as a target for type 2 diabetes.2 Proof of this concept was recently provided from clinical 
trials with 1 (TAK-875/fasiglifam), a selective FFA1 agonist that showed glucose lowering 
activity similar to the sulfonylurea glimepiride without the increased hypoglycemic events 
observed with glimepiride.3 Originally derived from the structure of docosahexaenoic acid 
(DHA),4 the pharmacology of 1 has turned out to be more complex than previously presumed. 
Rather than binding to the orthosteric free fatty acid binding site on FFA1, 1 was recently shown 
to be an allosteric agonist with the ability to positively modulate fatty acid actions at FFA1.5 In 
fact, studies using radiolabeled ligands have indicated that FFA1 possesses at least three distinct 
binding sites that recognize structurally closely related ligands and that each site is able to 
allosterically modulate ligand function at the others.6 The recently published crystal structure of 
FFA1 in complex with 1 lent further support to the concept of multiple FFA1 binding sites, 
revealing several potential binding sites in addition to the site of 1.7 Most importantly from a 
drug development standpoint, the specific binding site an FFA1 agonist interacts with may 
influence the ligand’s downstream signaling outcomes,2c and thus may have clear implications 
for the ultimate therapeutic efficacy of any developed FFA1 agonists. How these structurally 
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similar ligands interact with their distinct binding sites on FFA1 remains poorly understood and, 
therefore, there is a clear need to develop novel tools to assess ligand binding to this receptor. 
Ligands incorporating fluorescent probes have become common tools to assess ligand binding 
to GPCRs and offer a number of advantages over classic radiolabeled ligands.8 In addition to 
practical considerations of convenience, safety and cost, by utilizing solvatochromic 
fluorophores or combining with a resonance energy transfer assay format, fluorescent ligands 
provide the significant advantage of real-time detection of their binding. This allows for 
homogenous assay formats, improved measurements of ligand binding kinetics, and 
visualizations of receptor-ligand complexes within a living cell.8-9 Fluorescently-tagged FFA1 
ligands are, therefore, expected to be valuable tools for elucidation of the pharmacology of this 
very interesting antidiabetic target. 
Choice of fluorophore 
Commonly used fluorophores include relatively large structures such as fluorescein derivatives 
and especially BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) due to its several favorable 
properties.10 The smaller benzofurazan core structure is also well-known in fluorogenic and 
fluorescent reagents and represents a class of compounds that results in derivatives with good 
quantum yields and with excitation and emission wavelengths long enough to avoid interference 
from biological autofluorescence.11 Variation of substituents in the 4- and 7-position influences 
the electronic effects on the system and thereby the fluorescent properties.12 In this way the 
excitation and emission maxima as well as fluorescent intensity can be modified. The 4-nitro-7-
aminobenzofurazan (NBD) fluorophore is a relatively small fluorescent probe with excitation 
maximum around 470 nm and emission maximum around 530 nm when substituted with an 
amine in the 7-position,13 wavelengths well suited to in vitro biological systems. Furthermore, 
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NBD is solvatochromic, exhibiting very low fluorescent activity in polar and protic 
environments, but much increased fluorescence in hydrophobic environments such as protein 
binding pockets or the plasma membrane.14 These properties suggest an NBD fluorescent tracer 
may possess reduced background fluorescence from non-bound fluorescent tracer allowing for 
both homogenous detection and use in imaging applications. NBD has been used previously for 
labeling small amine containing molecules and proteins used in binding assays as well as for 
visualization in living cells.15 
Design of fluorescent FFA1-tracers 
We have previously reported on two series of agonists for FFA1 based on an alkyne scaffold 
and a benzyloxy/benzylamine scaffold, respectively, and we aimed at exploring both series in 
efforts to develop a potent fluorescent tool compound for FFA1 (Figure 1). 
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Figure 1. Design strategies of alkyne-based and benzyloxy-based fluorescent tracers. NBD, 
7-nitrobenzofurazan-4-yl.  
The first fluorescent tracer 2 is based on the alkyne series that includes 3 (TUG-770), a 
compound showing good potency and lower lipophilicity than most other FFA1 agonists.16 This 
is important because incorporation of a fluorophore generally erodes potency and, for uncharged 
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fluorophores, increases lipophilicity of the compounds thereby reducing their usefulness for in 
vitro pharmacology studies. Structure-activity relationship (SAR) investigations have shown that 
larger substituents at the alkyne scaffold are best tolerated in the meta-position of the terminal 
phenyl ring, but these lead to a loss in potency, which to some extent can be regained by 
introduction of a 2-fluoro substituent on the central phenyl ring.16-17 Thus, the 2-fluoro 
substituent was incorporated in the target structure and the spacer-extended fluorophore was 
attached to the meta-position of the terminal phenyl ring. A shorter 2-aminoethoxy and a longer 
2-(2-aminoethoxy)ethoxy tether were considered, however, the NBD-tethered compounds with 
the shorter 2-aminoethoxy spacer turned out to be unstable and decomposed before or during 
purification. Focus was therefore directed towards the longer linker. 
The second fluorescent tracer 4 was designed based on the benzylamine agonist 5 (TUG-905), 
a potent and selective agonist on both the human and rodent FFA1 receptors.18 The 2-fluoro 
substituent, shown to significantly enhance potency in the alkyne series,16 also in some cases 
enhances potency in the benzylamine and benzyloxy series and was incorporated in the target 
structure. The amine-linker was exchanged for the corresponding oxy-linker since this facilitates 
preparation and the modification has been shown to have only modest effect on ligand potency.19 
The mesylpropoxy appendage also present in the structurally related agonist 1, has been found to 
reduce lipophilicity of the compounds with little or no effect on potency.4b, 18 The crystal 
structure of FFA1 in complex with 1 provided an explanation for this in showing the 
mesylpropoxy appendage to be protruding from the ligand binding pocket towards the lipid 
bilayer.7 Thus, this seems to be an optimal linkage point for attachment of a spacer-extended 
fluorophore. In order to gain optimal fluorescent properties of the NBD fluorophore the 
compound should be attached to a primary aliphatic amine.12 Thus, we decided to explore 2-(2-
 7 
aminoethoxy)ethanol, which is slightly longer than the mesylpropoxy substituent but less 
lipophilic than an all carbon linker.  
RESULTS AND DISCUSSION 
Synthesis of tracer ligands 
The fluorescent tracer molecules 2 and 4 were synthesized by similar strategies. Tracer 2 was 
synthesized from the previously published alkyne intermediate 616 by alkylation with Boc-
protected 2-(2-aminoethoxy)ethyl tosylate to give 7,20 followed by concomitant acid catalyzed 
ester hydrolysis and Boc-deprotection to give the zwitterionic intermediate that was used directly 
in the reaction with NBD chloride and purification by preparative HPLC gave 2 in 24% yield 
from 6. 
Scheme 1. Synthesis of 2.a 
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a Reagents and conditions: (a) BocNH(CH2)2O(CH2)2OTs, K2CO3, MeCN, reflux, 3 h, 79%. 
(b) HCl(aq), THF, reflux, 2½ h, 57%. (c) NBDCl, NaHCO3, MeOH, 50 
°C, 4 h, 54%. 
Tracer molecule 4 was synthesized from 8, first by a Williamson ether synthesis to provide 9 
and further by a two-step one-pot borylation Suzuki cross-coupling using tetrahydroxydiboron as 
borylation agent and the second generation XPhos precatalyst to give 10 (Scheme 2).21 The 
fluorophore was installed by alkylation of the phenol of 10, deprotection of 11 and reaction with 
NBD chloride, as described for 2, to provide 4 in 8% overall yield from 8. 
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Scheme 2. Synthesis of 4.a 
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aReagents and conditions: (a) K2CO3, acetone, rt, 16 h, 81%. (b) BBA, XPhos, Pd-G2-XPhos, 
KOAc, EtOH, 80 °C, 2 h, then 4-bromo-3-methylphenol, 1.8 M K2CO3(aq), 80 °C, 16 h, 37%. (c) 
BocNH(CH2)2O(CH2)2OTs, K2CO3, MeCN, reflux, 23 h, 93%. (d) HCl(aq), THF, reflux 7 h. (e) 
NBDCl, NaHCO3, MeOH, 50 °C, 4 h, 28%. 
 
Characterization of fluorescent properties 
The fluorescent properties of the ligands were examined in Hanks’ balanced salt solution 
(HBSS) supplemented with calcium and magnesium, a standard aqueous buffer used for our in 
vitro pharmacological assays, and n-octanol mimicking a lipophilic environment to examine the 
solvatochromic effect of NBD. 
The excitation and emission maxima of 2 in n-octanol were within the desired range giving an 
acceptable Stokes shift (SS) of 64 nm (Table 1). As expected, the excitation and emission 
maxima were somewhat red-shifted in the aqueous medium (»ex = 483 nm & »em = 546 nm, 
Table 1 and Figure S1). Compound 4 showed excitation and emission maxima similar to 2 in 
both n-octanol and HBSS (SS = 65 nm, Figure 2A), however, the extinction coefficient was 2.7-
fold higher for 4. To investigate the influence of the solvatochromic effect of NBD, emission 
spectra of 4 were recorded in both n-octanol and HBSS using identical instrument settings. This 
showed, as expected, almost no fluorescent activity in the aqueous environment (Figure 2B), too 
low to determine the quantum yield. Background fluorescence from unbound excess tracer in 
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aqueous media should therefore not be an issue. Overall, both tracers demonstrated good 
fluorescent properties with 2 showing a somewhat higher quantum yield (Table 1). The initial 
biological characterization of these ligands at FFA1, however, found 4 to be superior with both 
EC50 and Kd-value in the nanomolar range.  
Table 1. Basic in vitro and fluorescent characterization of tracers. 
 
Ca2+ assay Binding Assay n-Octanol HBSS 
EC50
a
 
[nM] 
Kd
b
 
[nM] 
»ex 
[nm] 
»em 
[nm] 
SS 
[nm] 
µ  
[M-1cm-1] 
QY »ex [nm] »em [nm] 
2 >1,000c n.d.d 462 526 64 7969 ± 126 0.65 483 546 
4 187 7.4 ± 1.3 462 527 65 21820 ± 37 0.44 478 545 
aPotency of Ca2+ response in Flp-In T-REx 293 cells induced to express FFA1. bKd was 
determined from saturation BRET binding assay using 5 to define non-specific binding. c2 
generated an FFA1-dependent Ca2+ response, however its potency was too low to fit a 
concentration-response and establish an EC50 value. 
dNot determined. SS, Stokes shift; QY, 
quantum yield. 
 
 
Figure 2. Fluorescent properties of 4. A) Exitation & emission spectra. B) Solvent effect on 
emission spectra; n-octanol, HBSS, solid line ~ excitation, dotted line ~ emission. RLU, 
relative luminescence units. 
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Functional characterization of 2 and 4 
Initial functional characterization of 2 established that although the fluorophore remained an 
FFA1 agonist, it had substantially reduced potency compared to the parent compound 3. Indeed, 
its potency was too low to establish an accurate EC50 value (Table 1, Figure 3A). In contrast, 
while 4 also behaved as an agonist, this compound retained high potency, displaying only a small 
reduction compared to its parent 5 (Table 1, Figure 3B). This suggests the position of the linker 
and the NBD fluorophore in 4 has minimal impact on its interaction with FFA1, and that the 
molecule is likely to be a useful FFA1 tracer. 
  
Figure 3. High potency at FFA1 is maintained for the NBD labeled 4. A) Concentration-
response curves generated using Flp-In T-REx 293 FFA1-eYFP cells are shown for 2 and its 
parent compound 3. B) Concentration-response curves in these cells are shown for 4 and its 
parent compound 5. Data shown as mean ± S.E.M., n=3. 
Characterization of 4 as an FFA1 tracer 
Based on its high potency in the Ca2+ assay we developed an FFA1 binding assay utilizing this 
ligand as a tracer employing a bioluminescence resonance energy transfer (BRET)-based 
approach.22 This allows for a truly homogeneous ‘mix and measure’ assay, well suited for both 
detailed kinetic as well as high throughput equilibrium binding experiments. For this, FFA1 was 
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tagged at its N-terminus with the small, bright NanoLuciferase (NLUC), a bioluminescent 
enzyme with an emission spectrum that has excellent overlap with the NBD excitation spectrum 
(Figure 5A). Thus, when 4 binds to NLUC-FFA1, energy transfer at 460 nm can occur between 
the NLUC and NBD moiety, resulting in NBD emission at 545 nm. As BRET is strictly 
dependent on the distance between the bioluminescent and fluorescent partners, this approach 
eliminates the need to remove 4 from the assay medium and limits any signal obtained from the 
non-specific binding of 4 to the membrane (Figure 5B). 
 Figure 5. Compound 4 is suitable for use in a BRET-based binding assay. A) The emission 
spectrum of NLUC (blue stippled) along with the excitation (dark green) and emission (light 
green stippled) spectra of 4, as measured under binding assay conditions, are shown. The spectral 
overlap between NLUC emission and 4 excitation is marked by the diagonal green fill. B) A 
cartoon depicting the concept of the BRET binding assay is shown. Light is emitted from 
receptor bound NLUC at 460 nm and, through BRET, transferred only to the fluorophore in very 
close proximity. This in turn results in emission at 545 nm by the receptor bound fluorophore, 
but not by the unbound fluorophore in the medium, nor by the non-specifically bound 
fluorophore in the membrane. The solvatochromic properties of NBD should further reduce any 
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signal from unbound 4, due to reduced fluorescence from the molecules in the aqueous buffer 
environment vs those in the membrane (shown by different shade of green). 
 
Saturation BRET binding experiments with 4 showed low non-specific BRET at 
concentrations up to 100 nM (Figure 6A), a highly satisfactory result considering the 
lipophilicity of the compound (clogP = 7.77). This low ratio of total to non-specific signal 
allowed determination of the dissociation constant for 4 through equilibrium saturation binding 
experiments (Table 1, Figure 6A). Kinetic binding experiments were also conducted, establishing 
the off- and on-rates for 4 to be: koff = 0.166 ± 0.017 min
-1 and kon = 41,100,000 ± 7,800,000 min
-
1M-1 (Figure 6B). Independent derivation of the Kd for 4 from the kon and koff values yielded a Kd 
value of 4.0 nM, in close accord with the Kd value obtained from saturation binding experiments 
(Table 1). 
 
Figure 6. Saturation and kinetic binding experiments allow determination of the affinity of 4 at 
FFA1. A) A representative saturation binding experiment is shown, where non-specific binding 
is defined by co-incubation with 10 µM 5. Data shown are mean ± S.E.M. of technical 
triplicates. B) A representative kinetic binding experiment is shown. Association was initiated by 
the addition of 4 (100 nM) followed by the addition of 10 µM 5 at 5 min to prevent re-binding of 
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4 subsequent to dissociation of the fluorescent tracer. Data shown are mean ± S.E.M. of technical 
triplicates. 
Next, 4 was used as a tracer in competition binding assays to assess the affinity of previously 
published FFA1 agonists. Given the previous reports demonstrating multiple FFA1 binding 
sites,6-7 it was first important to determine which classes of FFA1 agonist do, and do not, bind 
competitively with 4. For this, competition binding experiments were conducted using the 
synthetic agonists 1, 3, 5, and 12 (GW9508),23 as well as with the endogenous agonist lauric 
acid, against varying concentrations of 4 (Figure S2). From these experiments, it was clear that 
each synthetic agonist fully competed with 4, even when the concentration of 4 was greater than 
20 times Kd. This strongly suggests that each of these compounds binds competitively with 4 to 
FFA1. By contrast, despite acting as an FFA1 agonist, lauric acid only resulted in a minor 
reduction of the specific binding signal of 4, suggesting that it does not bind competitively. This 
finding is consistent with previous reports that the fatty acids bind to a different site than many 
synthetic FFA1 agonists.5-6 Global curve fitting to an allosteric ternary complex model of the 
lauric acid data allowed for an estimation of its pKB (4.46 ± 0.15) and allosteric cooperativity 
factor (logα = -0.29 ± 0.09) values.  
Given that we observed all synthetic agonist classes to be competitive with 4, we next aimed to 
use this compound to assess the affinity of a range of previously reported FFA1 agonists. For 
these studies, in addition to parent compounds and analogues of 2 and 4, the first high-potency 
FFA1 agonist 12, the previous clinical candidates 13 (AMG-837)24 and 1, and Merck’s potent 
thiazolidinedione agonist 14 (Cmp B)25 were selected.23-26 Each of the selected molecules 
exhibited competitive binding with 4 that allowed estimation of Ki binding affinity constants 
(Table 2). 
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Table 2. Potency and binding affinity of selected FFA1 agonists.  
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 Competition binding  β-Arrestinb Calciumc 
 pKi
a pEC50 (% Emax) pEC50 (% Emax) 
1 7.54 ± 0.03 8.03 ± 0.13 (89) 7.24 ± 0.01 (108) 
3 7.07 ± 0.04 7.73 ± 0.06 (100) 8.23 ± 0.06 (100) 
5 8.36 ± 0.01 7.85 ± 0.02 (106)  8.04 ± 0.02 (102)d 
12 6.66 ± 0.05 7.55 ± 0.15 (86) 7.54 ± 0.03 (103)d 
13 7.38 ± 0.06 6.81 ± 0.50 (108) 6.77 ± 0.06 (105) 
14 7.16 ± 0.03 7.26 ± 0.03 (95) 6.75 ± 0.04 (103)d 
15 6.20 ± 0.05 7.17 ± 0.07 (100) 7.34 ± 0.07 (103)d 
16 6.69 ± 0.04 7.21 ± 0.10 (95) 7.70 ± 0.04 (103)d 
17 8.23 ± 0.03 7.95 ± 0.03 (114) 7.73 ± 0.04(114)d 
18 4.86 ± 0.02 6.26 ± 0.09 (90) 6.34 ± 0.02 (100)d 
Lauric acid –e 5.10 ± 0.06 (130) 6.12 ± 0.05 (116) 
apKi values obtained through displacement BRET binding assays containing 10 nM 4, n = 3.
 
bβ-arrestin pEC50 determined using BRET-β-arrestin recruitment assay. Emax expressed as % of 
3, n = 3. cCa2+ pEC50 were determined using FFA1-expressing 132N1 cells. Emax is expressed as 
% of 3. n = 3. dPreviously published.16-19 ePartial competition that fitted to an allosteric ternary 
complex model gave pKB = 4.46 and logα = -0.29 (see Figure S2). 
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Overall, good correlation between agonist potency and binding Ki-values was observed, with 5 
being both the most potent agonist in the functional assays and the ligand with the highest 
affinity (Table 2). Likewise, 1 and 13 showed Ki-values that were similar to their functional 
potency, and also similar to Ki-values previously established through a radiotracer competition 
binding assay.2c 14, which with a different core structure and a thiazolidinedione head group is 
the most structurally distinct from 4, also exhibited potency in the functional assays that 
corresponded well to its binding affinity. In contrast, 3, a highly potent agonist in both Ca2+ and 
β-arrestin-2 interaction-based functional assays, showed a 15- and 3-fold lower potency, 
respectively, in the binding assay. A similar observation was made with 12, also showing a much 
lower affinity for FFA1 than would be expected based on the functional data.  
To examine the discrepancy between potency and affinity of 3 more closely, derivatives of 3 
and 5 with varying functional potency were tested in competition binding assays. These studies 
included 3, 15 (TUG-424)27 and 16 (TUG-488)17 in the alkyne series and showed correct ranking 
within the series, i.e. 3 > 16 > 15, and excellent correlation between binding affinity and calcium 
mobilization (R2 = 0.967). Likewise, the functional SAR within the benzylamine/oxy 
dihydrocinnamic acid series including 5, 12, 17 (TUG-469)19 and 18 (TUG-20)19 shows correct 
ranking (5 > 17 > 12 >> 18) and good correlation between binding affinity and calcium 
mobilization (R2 = 0.913), whereas the β-substituted 13 and 1 were fitted well with the other 
benzylamine/oxy compounds (R2 = 0.709). The overall correlation is, however, relatively low 
(R2 = 0.345). Together this demonstrates that although the affinity obtained through competition 
with 4 generally correlates well with functional potency within a specific FFA1 agonist series, 
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the relationship between affinity and functional potency may vary between structurally distinct 
compounds.  
The discrepancy between affinity and potency across chemical series may be explained by 
differences in the intrinsic efficacy of these series to activate FFA1. Although all agonists tested 
appeared to be equal and full agonists in the Ca2+ assay, it is well established that in Ca2+ assays, 
which have a high level of signal amplification, differences in intrinsic efficacy of a ligand will 
often manifest as increased potency, due to the presence of a receptor reserve.28 It could also be 
related to kinetic properties where slow and fast ligands may have distinct functional activities 
but will appear to have the same affinity as long as the ratios between their on- and off-rates are 
the same. It is therefore possible that at least some aspects of the discrepancy between potency 
and affinity observed for certain chemical series of FFA1 agonists could be related to binding 
kinetics. A third factor that may contribute to the discrepancy is the apparent presence of the 
multiple binding sites in FFA1,5-6 implying the possibility of partial or lack of overlap with 4. In 
line with these observations, lauric acid was found to behave as an allosteric compound 
incompetent to fully displace 4, in contrast to the synthetic agonists that all behaved as fully 
competitive with 4, indicating at least partially overlapping binding sites. Taken together, these 
findings demonstrate that a full characterization of both binding affinity and functional potency 
will be critical to understanding the pharmacology of novel FFA1 compounds.  
CONCLUSION 
Taking advantage of established SAR of known agonists, we have developed fluorescent FFA1 
tracers by tethering of the NBD fluorophore to potent core structures. This resulted in the 
identification of 4, a high affinity fluorescent tracer molecule with a favorable specific to non-
specific binding signal at up to 100 nM concentration. The compound possesses good 
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spectroscopic properties with close to absent fluorescence in aqueous environments but a high 
quantum yield, extinction coefficient and Stokes shift in non-polar environments. We have 
demonstrated the efficient use of 4 in a homogenous ‘mix and measure’ BRET-based binding 
assay suitable for both detailed kinetic studies and high throughput competition binding studies. 
This establishes 4 as a valuable tool in future drug discovery efforts targeting FFA1. 
EXPERIMENTAL SECTION 
Synthesis 
Commercial starting materials and solvents were used without further purification, unless 
otherwise stated. THF was freshly distilled from sodium/benzophenone. MeOH and MeCN were 
dried over 3 Å sieves. K2CO3 was dried and stored in an oven. TLC was performed on TLC 
silica gel 60 F254 plates and visualized at 254 or 365 nm or by staining with phosphomolybdic 
acid, ninhydrin, FeCl3 or KMnO4 stains. Purification by flash chromatography was carried out 
using silica gel 60 (0.040-0.063 mm, Merck). 1H, 13C and 19F NMR spectra were recorded at 400, 
101, and 376 MHz, respectively, on Bruker Avance III 400 at 300 K. HPLC analysis was 
performed using a Gemini C18 column (5 µm, 4.6x150 mm); flow: 1 mL/min; 10% MeCN in 
water (0-1 min), 10-100% MeCN in water (1-10 min), 100% MeCN (11-15 min), with both 
solvents containing 0.1% HCOOH as modifier; UV detection at 254 nm. HPLC purification was 
performed by using a Phenomenex Luna C18 column (5 µm, 250×21.20 mm) with gradient 
elution of MeCN and H2O, with both solvents containing 0.1% HCOOH as modifier. High-
resolution mass spectra (HRMS) were obtained on a Bruker micrOTOF-Q II (ESI). Purity was 
determined by HPLC and confirmed by inspection of NMR spectra. The purity of all test 
compounds were >95%. 
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3-(2-Fluoro-4-((3-(2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)ethoxy)-
phenyl)ethynyl)phenyl)propanoic acid (2). Step 1: 7 (176 mg, 0.36 mmol) was dissolved in 
THF (4 mL). 4M HCl(aq) (2 mL) was added and the reaction was heated to reflux for 2½ h. After 
complete hydrolysis the reaction was cooled to room temperature and 2M NaOH(aq) (4 mL) was 
added. The mixture was extracted with EtOAc (x3). Additional 2M NaOH(aq) (2 mL)  was added 
to the water phase and this was extracted once more with EtOAc (x3). The combined organic 
phases was dried over MgSO4 and concentrated in vacuo to give 103 mg (76%) of a white solid: 
tR = 8.74 min (94.5%); 
1H NMR (400 MHz, DMSO) ´  12.10 (br s, 1H), 8.30 (br s, 2H), 7.41–
7.30 (m, 4H), 7.16–7.10 (m, 2H), 7.06–7.01 (m, 1H), 4.22–4.14 (m, 2H), 3.84–3.77 (m, 2H), 
3.72 (t, J = 5.3 Hz, 2H), 2.96 (t, J = 5.3 Hz, 2H), 2.87 (t, J = 7.4 Hz, 2H), 2.56 (t, J = 7.5 Hz, 
2H); 13C NMR (101 MHz, DMSO) ´  173.3, 160.1 (d, J = 244.7 Hz), 158.3, 131.0 (d, J = 5.6 Hz), 
130.0, 128.8 (d, J = 15.9 Hz), 127.6 (d, J = 3.1 Hz), 123.9, 123.0, 121.8 (d, J = 9.9 Hz), 117.7 (d, 
J = 23.9 Hz), 116.7, 116.1, 89.7, 87.9 (d, J = 3.1 Hz), 68.7, 67.2, 66.7, 38.3, 33.5, 23.6 (d, J = 2.1 
Hz); ESI-HRMS calcd for C21H23FNO4 (M+H
+) 372.1606, found 372.1593. 
Step 2: A dry microwave vial under argon atmosphere was charged with the deprotected crude 
compound from Step 1 (14 mg, 0.04 mmol), MeOH (1 mL), NaHCO3 (14 mg, 0.16 mmol) and 4-
chloro-7-nitrobenzo[c][1,2,5]oxadiazole (NBD-Cl, 23 mg, 0.12 mmol). The reaction was 
covered with aluminum foil and stirred at 50oC for 4 hours. Afterwards the reaction was 
concentrated under a stream of nitrogen. The residue was dissolved in a mixture of EtOAc and 
1M HClaq. The organic phase was washed with water, brine, dried over Na2SO4 and concentrated 
in vacuo. The crude was dissolved in minimum amount of MeCN and MeOH and purified by 
preparative HPLC with fraction collection at 365 nm using MeCN and milliQ water both 
containing 0.1% formic acid as modifier. The compound fraction was pooled, concentrated in 
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vacuo and extracted with EtOAc (x2). The organic phases were combined, washed with brine, 
dried over Na2SO4 and concentrated in vacuo to give 11 mg (54%) of 2 as an orange solid (tR = 
12.33 min, purity >99% by HPLC). All handling was performed in dimmed lightning and 
solutions were stored in aluminum foil-covered glassware. 1H NMR (400 MHz, DMSO-d6) ´  
8.32 (d, J = 7.5 Hz, 1H), 7.48–7.28 (m, 6H), 7.20–7.07 (m, 3H), 7.00 (d, J = 7.5 Hz, 1H), 6.37 
(d, J = 8.5 Hz, 1H), 4.24–4.15 (m, 3H), 3.93–3.81 (m, 5H), 3.79–3.66 (m, 2H), 2.89 (t, J = 7.2 
Hz, 3H), 2.50 (t, J = 7.5 Hz, 3H); ESI-HRMS calcd for C27H23FN4NaO7 (M+Na)
+ 557.1443, 
found 557.1416. 
3-(2-Fluoro-4-((2'-methyl-4'-(2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-
yl)amino)ethoxy)ethoxy)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)propanoic acid. (4) Step 1: 
Boc-protected amine 11 (83 mg, 0.14 mmol) was dissolved in THF (1.7 mL) and 4M HClaq (0.8 
mL) was added. The reaction was refluxed for 7 hours and after completion cooled to room 
temperature. 2M NaOHaq (3 mL) was added and the mixture was extracted with EtOAc/MeOH 
(9:1, x3). The organic phases were collected, dried over Na2SO4 and concentrated in vacuo 
giving the zwitterion as a beige solid that was used directly in the next step. 
Step 2: A dry flask under argon with magnetic stirring bar was charged with the crude material 
from Step 1 (0.14 mmol), MeOH (3.7 mL), NaHCO3 (37 mg, 0.45 mmol) and 4-chloro-7-
nitrobenzo[c][1,2,5]oxadiazole (NBD-Cl, 86 mg, 0.43 mmol). The reaction was covered with 
aluminum foil and heated to 50oC for 4¼ hours. The reaction was concentrated under a gentle 
flow of nitrogen and the crude was dissolved in 1 M HClaq and EtOAc. The mixture was 
extracted and phases separated, and the water phase was extracted once more with EtOAc. The 
organic phases were combined, washed with brine and dried over Na2SO4. The residue was 
concentrated and stored in the freezer overnight. The crude was dissolved in MeCN (1.5 mL) and 
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MeOH (0.5 mL) and purified by preparative HPLC with fraction collection at 365 nm using 
MeCN and milliQ water both containing 0.1% formic acid as modifier. The compound fraction 
was pooled, concentrated in vacuo and extracted with EtOAc (x2). The organic phases were 
combined, washed with brine, dried over Na2SO4 and concentrated in vacuo to give 24 mg (28% 
over 2 steps) of 4 as an orange solid (tR = 12.98 min, purity >98.6% by HPLC). All handling was 
performed in dimmed lightning and solutions were stored in aluminum foil-covered glassware. 
1H NMR (400 MHz, DMSO) ´  12.14 (s, 1H), 9.49 (br s, 1H), 8.48 (d, J = 9.1 Hz, 1H), 7.46–7.36 
(m, 2H), 7.35–7.31 (m, 1H), 7.26–7.17 (m, 2H), 7.06–7.01 (m, 1H), 6.90–6.78 (m, 2H), 6.76–
6.71 (m, 2H), 6.49 (d, J = 9.0 Hz, 1H), 5.13 (s, 2H), 4.10–4.06 (m, 2H), 3.80 (dd, J = 10.1, 5.2 
Hz, 4H), 3.70 (br s, 2H), 2.76 (t, J = 7.5 Hz, 2H), 2.48–2.43 (m, 2H), 2.13 (s, 3H); ESI-HRMS 
calcd for C31H31FN4NaO8 (M+Na)
+ 653.2018, found 653.1995. 
Methyl 3-(4-((3-(2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethoxy)phenyl)ethynyl)-2-
fluorophenyl)propanoate (7). 2-(2-(N-Boc-amino)ethoxy)ethyl tosylate (276 mg, 0.77 mmol), 6 
(149 mg, 0.50 mmol), MeCN (2 mL) and K2CO3 (147 mg, 1.06 mmol) was added to a dry flask 
under argon. The reaction was refluxed for 3½ h, cooled to room temperature and diluted with 
water before extraction with EtOAc (x3). The combined organic phases were washed with brine, 
dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography 
(SiO2, EtOAc:petroleum ether, 1:3) to give 192 mg (79%) of a white solid: Rf = 0.40 
(EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, CDCl3) ´  7.29–7.15 (m, 4H), 7.14–7.10 (m, 
1H), 7.09–7.05 (m, 1H), 6.93 (dd, J = 8.3, 1.8 Hz, 1H), 4.97 (br s, 1H), 4.18–4.09 (m, 2H), 3.87–
3.79 (m, 2H), 3.68 (s, 3H), 3.62 (t, J = 5.1 Hz, 2H), 3.40–3.29 (m, 2H), 2.99 (t, J = 7.7 Hz, 2H), 
2.64 (t, J = 7.7 Hz, 2H), 1.45 (s, 9H); 13C NMR (101 MHz, CDCl3) ´  172.9, 160.6 (d, J = 246.3 
Hz), 158.5, 130.6 (d, J = 5.6 Hz), 129.5, 128.1 (d, J = 16.0 Hz), 127.5 (d, J = 3.2 Hz), 124.5, 
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123.9, 123.1 (d, J = 9.8 Hz), 118.3 (d, J = 23.8 Hz), 117.2, 115.8, 89.8, 88.0 (d, J = 3.3 Hz), 
79.3, 70.5, 69.4, 67.4, 51.7, 40.4, 34.0, 28.4, 24.6 (d, J = 2.3 Hz).  
Ethyl 3-(4-((3-bromobenzyl)oxy)-2-fluorophenyl)propanoate (9). A flask was charged with 
3-bromobenzyl bromide (256 mg, 1.03 mmol), 8 (203 mg, 0.96 mmol), K2CO3 (281 mg, 2.03 
mmol) and acetone (5 mL), and the reaction mixture was stirred at room temperature for 16 
hours. After completion, as indicated by TLC, the reaction was diluted with water and extracted 
with EtOAc (x3). The organic phases were combined, washed with brine, dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by flash chromatography (SiO2, 
EtOAc:petroleum ether, 1:6) to give 297 mg (81%) of 9 as a clear oil: Rf = 0.39 
(EtOAc:petroleum ether, 1:4); 1H NMR (400 MHz, CDCl3) ´  7.59–7.55 (m, 1H), 7.49–7.44 (m, 
1H), 7.35–7.31 (m, 1H), 7.28–7.23 (m, 1H), 7.14–7.08 (m, 1H), 6.70–6.61 (m, 2H), 4.99 (s, 2H), 
4.12 (q, J = 7.1 Hz, 2H), 2.91 (t, J = 7.7 Hz, 2H), 2.59 (t, J = 7.7 Hz, 2H), 1.23 (t, J = 7.1 Hz, 
3H); 13C NMR (101 MHz, CDCl3) ´  172.9, 161.6 (d, J = 245.6 Hz), 158.4 (d, J = 10.9 Hz), 
139.1, 131.3, 131.1 (d, J = 6.8 Hz), 130.5, 130.3, 126.0, 122.9, 120.0 (d, J = 16.2 Hz), 110.6 (d, J 
= 3.1 Hz), 102.8 (d, J = 25.7 Hz), 69.5, 60.6, 34.8 (d, J = 1.2 Hz), 24.2 (d, J = 2.1 Hz), 14.4; ESI-
HRMS calcd for C18H18BrFNaO3 (M+Na)
+ 403.0316, found 403.0300. 
Ethyl 3-(2-fluoro-4-((4'-hydroxy-2'-methyl-[1,1'-biphenyl]-3-yl)methoxy)phenyl)-
propanoate (10). A Schlenk flask with magnetic stirring bar under N2 flow was charged with 
tetrahydroxydiboron (BBA, 135 mg, 1.51 mmol), KOAc (152 mg, 1.54 mmol), Xphos (5 mg, 
2mol%), Xphos-Pd-G2 (4 mg, 1mol%) and 9 (180 mg, 0.47 mmol) dissolved in EtOH (5 mL). 
The mixture was evacuated and backfilled with argon (x3) and heated to 80oC. After 1½ hour the 
reaction had turned orange and 1.8M K2CO3aq (0.9 mL) and 4-bromo-3-methylphenol (121 mg, 
0.65 mmol) dissolved in EtOH (0.5 mL) was added. The mixture was evacuated and backfilled 
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with argon (x3) once again and at stirred at 80oC overnight. The reaction was cooled to room 
temperature, diluted with water and extracted with EtOAc (x3). The organic phases were 
combined, washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was 
purified by flash chromatography (SiO2, EtOAc:petroleum ether, 1:4) to give 71mg (37%) of 10 
as a red sticky oil: Rf = 0.14 (EtOAc:petroleum ether, 1:4); 
1H NMR (400 MHz, CDCl3) ´  7.44–
7.32 (m, 3H), 7.28–7.24 (m, 1H), 7.13–7.07 (m, 2H), 6.77–6.65 (m, 4H), 5.06 (s, 2H), 4.87 (s, 
1H), 4.12 (q, J = 7.1 Hz, 2H), 2.91 (t, J = 7.7 Hz, 2H), 2.59 (t, J = 7.7 Hz, 2H), 2.21 (s, 3H), 1.23 
(t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) ´  173.0, 161.6 (d, J = 245.3 Hz), 158.7 (d, J = 
10.9 Hz), 155.0, 142.1, 137.2, 136.5, 134.5, 131.2, 131.0 (d, J = 6.8 Hz), 129.3, 128.7, 128.5, 
125.8, 119.7 (d, J = 16.2 Hz), 117.1, 112.9, 110.7, 102.8 (d, J = 25.7 Hz), 70.5, 60.6, 34.9 (d, J = 
1.1 Hz), 24.2 (d, J = 1.9 Hz), 20.7, 14.3; ESI-HRMS calcd for C25H25FNaO4 (M+Na)
+ 431.1629, 
found 431.1610. 
Ethyl 3-(4-((4'-(2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethoxy)-2'-methyl-[1,1'-
biphenyl]-3-yl)methoxy)-2-fluorophenyl)propanoate (11). A flask under argon was charged 
with 7 (64 mg, 0.16 mmol), K2CO3 (62 mg, 0.45 mmol) and 2-(2-(N-Boc-amino)ethoxy)ethyl 
tosylate (123 mg, 0.34 mmol) dissolved in MeCN (4 mL), and the mixture was refluxed for 23 
hours. The reaction was cooled to room temperature, diluted with water and extracted with 
EtOAc (x3). The organic phases were combined, washed with brine, dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by flash chromatography (SiO2, 
EtOAc:petroleum ether, 1:2) to give 87 mg (93%) of 11 as a clear sticky oil: Rf = 0.15 
(EtOAc:petroleum ether, 1:3); 1H NMR (400 MHz, CDCl3) ´  7.44–7.32 (m, 3H), 7.29–7.24 (m, 
1H), 7.17–7.07 (m, 2H), 6.86–6.79 (m, 2H), 6.72–6.65 (m, 2H), 5.06 (s, 2H), 4.18–4.07 (m, 4H), 
3.86–3.80 (m, 2H), 3.63 (t, J = 5.2 Hz, 2H), 3.36 (d, J = 5.2 Hz, 2H), 2.90 (t, J = 7.7 Hz, 2H), 
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2.58 (t, J = 7.7 Hz, 2H), 2.23 (s, 3H), 1.45 (s, 9H), 1.23 (t, J = 7.1 Hz, 3H); ESI-MS m/z 618.3 
(M+Na+). 
Characterization of excitation and emission properties of fluorescent ligands for FFA1 
Absorbance curves and extinction coefficients for fluorescent ligands dissolved in either n-
octanol or HBSS (with Ca2+ and Mg2+) were measured in triplicate using a FLUOstar Omega 
Microplate Reader (BMG LAB-TECH).  
Emission curves for fluorescent ligands were measured in duplicate using a ChronosFD time-
resolved spectrofluorometer coupled to PMT detectors. All compounds were excited at a fixed 
excitation wavelength of 402 nm, and courmarin 153 (C-153) in EtOH was used as an internal 
standard for determination of quantum yield (¦ C-153 = 0.546, »ex = 402 nm)
29. All experiments 
were performed at 25°C. 
Ca2+ mobilization 
Ca2+ mobilization experiments were conducted using either Flp-In T-REx 293 cells engineered 
to express FFA1-eYFP in an inducible fashion in response to the antibiotic doxycycline, or in 
N1-FFA1 cells that constitutively expressed untagged FFA1. Cells were plated (50,000/well for 
Flp-In T-REx 293 cells or 15,000/well for N1-FFA1 cells) in black with clear bottom 96 well 
cell culture plates 24 h prior to experiments. At the time of plating the Flp-In T-REx 293 cells 
were also treated with 100 ng/ml doxycycline to induce FFA1-eYFP expression. Prior to the 
assay cells were loaded for 45 min with the Ca2+ dye, Fura-2 AM. Cells were then washed three 
times and incubated for 15 minutes in HBSS. Fura-2 fluorescent emission at 510 nm resulting 
from 340 or 380 nm excitation was then monitored using a Flexstation plate reader (Molecular 
Devices, Sunnyvale, CA, USA), both before and for 90 s after the addition of test compounds. 
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The peak 340/380 ratio obtained after compound addition was then used to plot concentration-
response data and determine compound potency. 
β Arrestin-2 BRET 
Plasmids encoding human FFA1 fused at its C-terminal to enhanced yellow fluorescent protein 
was co-transfected into HEK 293 cells with a plasmid encoding ² -arrestin-2 fused to Renilla 
luciferase. Cells were distributed into white 96-well plates 24 h post-transfection and then 
maintained in culture for another 24 h prior to their use. To conduct the assay, cells were first 
washed in HBSS and then the Renilla luciferase substrate coelenterazine h (2.5 µM) and the 
ligand of interest were added. Cells were incubated at 37 °C for 5 min before luminescence at 
535 and 475 nm was measured using a Pherastar FS plate reader. The ratio of luminescence at 
535/475 nm was then used to calculate the BRET response. 
Development of NLUC-FFA1 construct and cell line 
In order to develop a BRET binding assay a DNA construct was first generated using a 
seamless DNA assembly kit (Life Technologies) encoding the NLUC sequence immediately 
upstream and in-frame with the FFA1 coding sequence. To ensure proper cell surface delivery, 
the signal peptide sequence of the mGluR5 glutamate receptor was also included immediately 
upstream of the NLUC coding sequence. This construct was then transfected into Flp-In T-REx 
293 cells to generate a stable inducible cell line that expresses NLUC-FFA1 in response to 
doxycycline. The functionality of this construct and cell line to responded to FFA1 agonists was 
demonstrated through Ca2+ assays. 
Equilibrium BRET binding assay 
NLUC-FFA1 Flp-In T-REx 293 cells were induced to express the receptor construct by 
treatment for 24 h with 100 ng/ml doxycycline. Cells were then harvested and used to make total 
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cell membrane preparations according to a previously described protocol.30 Membranes were 
then resuspended in assay buffer (50 mM HEPES, 100 mM NaCl, 10 mM CaCl2, 10 mM MgCl2) 
and distributed into the wells of a white 96 well plate (5µg membrane protein/well). Membranes 
were then co-incubated with the indicated concentration of 4 (and 5 for non-specific binding 
measurements; or competing ligand for competition experiments) for 1 h at 25 °C. Following 
incubation, the NLUC substrate, Nano-Glo (Promega) was added to a final 1:800 dilution. 
Membranes were incubated a further 5 minutes before the bioluminescent emission at 460nm 
and 545 nm was measured using a Clariostar plate reader (BMG labtech). The ratio of 545/460 
was then background subtracted and multiplied by 1000 to yield ‘Net mBRET’ units. Total and 
non-specific saturation binding data were then globally fit to a one-site binding model using 
Graphpad Prism v6. Competition binding experiments were fit to a one-site model, and used to 
calculate pKi values based on a Kd value for 4 of 7.4 nM. 
Kinetic BRET binding assay 
For kinetic BRET binding assays, cell membranes were generated as for the equilibrium 
binding assay and again distributed in white 96 well microplates (2.5 µg membrane 
protein/well). The Nano-Glo substrate was then added (1:800 final dilution) before incubation 
for 5 min at 25 °C. Plates were then inserted into a Clariostar plate reader, with temperature set 
to 25 °C and set to read bioluminescent emission at 460 nm and 545 nm at 20 s intervals. After 
60 s, association experiments were initiated by the injection of 4 (100 nM final concentration) 
into the reaction using the Clariostar injectors. Readings were continued at 20 s intervals. 5 min 
after 4 had been added dissociation experiments were initiated by the injection of 5 (to a 10 µM 
final concentration), and readings were taken for a further 15 min. In all kinetic experiments 
parallel wells were run where 5 had been pre-added and these were used to subtract the non-
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specific binding signal for 4. Kinetic binding data were then fit to a combined association then 
dissociation model using Graphpad Prism v6 in order to obtain estimates of Koff, Kon and Kd. 
ASSOCIATED CONTENT 
Supporting Information. Absorption and emission spectra of 2. Competition binding curves for 
1, 3, 5, 12 and lauric acid. This material is available free of charge via the Internet at 
http://pubs.acs.org. 
AUTHOR INFORMATION 
Corresponding Author 
*Tel: +45 6550 2568. E-mail: ulven@sdu.dk 
Author Contributions 
The manuscript was written through contributions of all authors. All authors have given approval 
to the final version of the manuscript.  
Funding Sources 
The study has been funded by the Danish Council for Independent Research | Technology and 
Production Sciences (grant 09-070364), the Danish Council for Strategic Research (grant 11-
116196) and the University of Southern Denmark. EC is supported by a fellowship from the 
Lundbeck Foundation. BDH is supported by a fellowship from the University of Glasgow. 
Notes 
BDH, GM and TU are shareholders of Caldan Therapeutics. 
ACKNOWLEDGMENT 
We thank Lone Overgaard Storm for excellent technical assistance. 
 27 
ABBREVIATIONS 
7TM, seven transmembrane; BODIPY, 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene; BRET, 
bioluminescence resonance energy transfer; DHA, docosahexaenoic acid; FFA1, free fatty acid 
receptor 1; HBSS, Hanks’ balanced salt solution; NBD, 4-nitro-7-aminobenzodiazole; NLUC, 
NanoLuciferase; SS, Stokes shift; RLU, relative luminescence units; XPhos, 2-
dicyclohexylphosphino-2’,4’,6’-triisopropylbiphenyl. 
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Absorption & emission spectra of 2 
 
Figure S1. Normalized absorption and emission spectra of 2.  n-octanol, Hank’s buffer, 
solid line ~ excitation, dotted line ~ emission. 
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Competition binding curves for synthetic agonists and lauric acid 
 
Figure S2. The synthetic agonists 1 (TAK-875), 3 (TUG-770), 5 (TUG-905) and 12 (GW9508), but 
not the saturated fatty acid, lauric acid, bind competitively to FFA1 with 4. Competition BRET 
binding curves were generated using 5, 30 and 100 nM concentrations of 4 against 1 (A), 3 (B), 5 
(C), 12 (D), and lauric acid (E). Each of the synthetic ligands in A-D fully displaced 4 at all three 
concentrations, and therefore data were fit to determine pKi. Lauric acid did not fully compete with 
4, and therefore was fit to an allosteric ternary complex model to determine pKB and logα. Data 
shown are representative of triplicate experiments. 
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